Efficacy And Safety Alteplase for Acute Ischemic Stroke

Abstract

Background: Worldwide, 16.5 million people experience a stroke each year, with 5.7 million losing their lives as a direct result. This accounts for 11.5% of all deaths globally, according to the World Health Organization. Master administration rules issued by the European Stroke Association and American Stroke Association/American Heart Affiliation prescribe that alteplase is managed inside 4.5 hours of stroke side effect onset and now not indicate an upper age restrain. There is currently no more compelling intravenous treatment for AIS than alteplase-based intravenous thrombolysis. To improve prognosis for patients with acute ischemic stroke (AIS), alteplase intravenous thrombolysis administered within 4.5 hours after onset is recommended. Thus, this study set out to assess alteplase's effectiveness, safety, and effectivity in treating acute ischemic stroke.

Methods: This meta-analysis was performed according to the PRISMA guidelines. PubMed, Cochrane Library, and Sciences Direct literature searches, using alteplase, acute ischaemic stroke, as a keywords was conducted in March 2024. Statistical analysis uses Review Manager version 5.4.

Results: Based on these findings, a statistically significant difference in the improvement of NIHSS between baseline and 24 hours OR 1.21 CI 95%; (1.04 – 1.40) and adverse events OR 1.24 CI 95%; (1.06 -1.46).

Conclusions: Although administration of alteplase may reduce the severity of stroke, there is a risk of increased incidence of adverse events such as intracranial haemorrhage.